1. Home
  2. TTGT vs REPL Comparison

TTGT vs REPL Comparison

Compare TTGT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TTGT
  • REPL
  • Stock Information
  • Founded
  • TTGT 1999
  • REPL 2015
  • Country
  • TTGT United States
  • REPL United States
  • Employees
  • TTGT N/A
  • REPL N/A
  • Industry
  • TTGT Telecommunications Equipment
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • TTGT Telecommunications
  • REPL Health Care
  • Exchange
  • TTGT Nasdaq
  • REPL Nasdaq
  • Market Cap
  • TTGT 810.0M
  • REPL 816.4M
  • IPO Year
  • TTGT 2007
  • REPL 2018
  • Fundamental
  • Price
  • TTGT $29.01
  • REPL $10.80
  • Analyst Decision
  • TTGT Strong Buy
  • REPL Strong Buy
  • Analyst Count
  • TTGT 6
  • REPL 4
  • Target Price
  • TTGT $38.17
  • REPL $17.00
  • AVG Volume (30 Days)
  • TTGT 141.0K
  • REPL 432.6K
  • Earning Date
  • TTGT 11-12-2024
  • REPL 11-12-2024
  • Dividend Yield
  • TTGT N/A
  • REPL N/A
  • EPS Growth
  • TTGT N/A
  • REPL N/A
  • EPS
  • TTGT N/A
  • REPL N/A
  • Revenue
  • TTGT $226,314,000.00
  • REPL N/A
  • Revenue This Year
  • TTGT $2.45
  • REPL N/A
  • Revenue Next Year
  • TTGT $8.79
  • REPL $469.74
  • P/E Ratio
  • TTGT N/A
  • REPL N/A
  • Revenue Growth
  • TTGT N/A
  • REPL N/A
  • 52 Week Low
  • TTGT $22.82
  • REPL $4.92
  • 52 Week High
  • TTGT $41.93
  • REPL $12.97
  • Technical
  • Relative Strength Index (RSI)
  • TTGT 50.90
  • REPL 38.50
  • Support Level
  • TTGT $28.68
  • REPL $11.45
  • Resistance Level
  • TTGT $33.12
  • REPL $12.73
  • Average True Range (ATR)
  • TTGT 1.35
  • REPL 0.69
  • MACD
  • TTGT -0.12
  • REPL -0.16
  • Stochastic Oscillator
  • TTGT 20.35
  • REPL 8.82

About TTGT TechTarget Inc.

TechTarget Inc is a data, software and analytics leader for purchase intent-driven marketing and sales data which delivers business impact for business-to-business (B2B) companies. The company solutions are designed to enable B2B technology companies to identify, reach, and influence key enterprise technology decision makers faster and with higher efficacy. Geographically, it derives a majority of its revenue from North America. Its products and services intended to improve information technology vendors abilities to impact targeted audiences for business growth using targeting, first-party analytics and data services complemented with customized marketing programs that integrate content creation, demand generation, brand marketing, and other advertising techniques.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: